{"id":254297,"date":"2012-07-23T19:23:16","date_gmt":"2012-07-23T19:23:16","guid":{"rendered":"http:\/\/www.eugenesis.com\/gen9-sponsors-contest-to-recognize-innovation-in-synthetic-biology\/"},"modified":"2012-07-23T19:23:16","modified_gmt":"2012-07-23T19:23:16","slug":"gen9-sponsors-contest-to-recognize-innovation-in-synthetic-biology","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/gen9-sponsors-contest-to-recognize-innovation-in-synthetic-biology.php","title":{"rendered":"Gen9 Sponsors Contest to Recognize Innovation in Synthetic Biology"},"content":{"rendered":"<p><p>    CAMBRIDGE, Mass.--(BUSINESS WIRE)--  <\/p>\n<p>    Gen9, Inc., a pioneer in the development of scalable    technologies for synthesizing and assembling DNA, today    announced that it has underwritten the first annual G-Prize to    celebrate and support innovation in synthetic biology. The    inaugural G-Prize contest, conceived and exclusively sponsored    by Gen9, was launched to foster creative and innovative    approaches for using synthetic DNA constructs to advance    industries including chemical and enzyme production, biofuels,    pharmaceuticals, and even data storage.  <\/p>\n<p>    Most biotechnologies have not yet been imagined, let alone    made true, said Dr. Drew Endy of Stanford Bioengineering and a    Gen9 co-founder. I am thrilled that Gen9 has decided to enable    a diverse research community to dream bigger and make true    their ideas via better access to critical bioengineering    tools.  <\/p>\n<p>    Gen9 has developed unique, next-generation technologies for    synthesizing and assembling DNA constructs for use in    commercializing DNA synthesis and fabrication platforms. Today,    Gen9 is manufacturing and shipping double-stranded GeneBits    DNA constructs, or gene fragments from 500 to 1,024 base pairs    long, with a capacity to generate tens of thousands of    synthetic gene fragments per year in just a few square feet of    laboratory space.  <\/p>\n<p>    Synthetic biology represents perhaps the greatest opportunity    to modernize industry at Moores law scale since silicon,    said Kevin Munnelly, President and Chief Executive Officer of    Gen9. The market size for products that can be transformed    using synthetic biology is estimated to be multi-billions. We    look forward to hearing from the innovative community of    researchers who have big ideas for constructively building on    the many important industries ripe for modernization via    synthetic biology.  <\/p>\n<p>    The G-Prize contest is open to researchers working at academic    or public-benefit organizations only. Entries will be judged by    a panel of experts selected by Gen9. Any intellectual property    rights specific to an entry will remain the sole property of    the contestants or their institution. Four winners will be    chosen in the following categories: 1st Place (500    GeneBits, up to 500kb); 2nd Place (300 GeneBits, up    300kb) and; two awards for 3rd Place (100 GeneBits,    up to 100kb to two teams). Based on the current average market    cost of DNA constructs, the total market value of these prizes    exceeds $500,000.  <\/p>\n<p>    Deadline for entries is September 30, 2012. For more    information, please visit     <a href=\"http:\/\/www.gen9bio.com\/g-prize\" rel=\"nofollow\">http:\/\/www.gen9bio.com\/g-prize<\/a>.  <\/p>\n<p>    About Gen9  <\/p>\n<p>    Gen9 is building on advances in synthetic biology to power a    scalable fabrication capability that will significantly    increase the worlds capacity to compile DNA content. The    privately held companys next-generation DNA synthesis    technology allows for the high-throughput, automated production    of DNA constructs at lower cost and higher accuracy than    previous methods on the market. Founded by world leaders in    synthetic biology, Gen9 aims to ensure the constructive    application of synthetic biology in industries ranging from    enzyme and chemical production to pharmaceuticals and biofuels.    Gen9 is based in Cambridge, Massachusetts and can be found    online atwww.Gen9bio.com.  <\/p>\n<p>    Gen9, GeneBits and BioFab are trademarks or registered    trademarks of Gen9, Inc. All other brands may be trademarks of    their respective holders.  <\/p>\n<\/p>\n<p>Continue reading here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/gen9-sponsors-contest-recognize-innovation-120000699.html;_ylt=A2KJNF.epA1Qrj8APhb_wgt.\" title=\"Gen9 Sponsors Contest to Recognize Innovation in Synthetic Biology\">Gen9 Sponsors Contest to Recognize Innovation in Synthetic Biology<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gen9, Inc., a pioneer in the development of scalable technologies for synthesizing and assembling DNA, today announced that it has underwritten the first annual G-Prize to celebrate and support innovation in synthetic biology. The inaugural G-Prize contest, conceived and exclusively sponsored by Gen9, was launched to foster creative and innovative approaches for using synthetic DNA constructs to advance industries including chemical and enzyme production, biofuels, pharmaceuticals, and even data storage.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/gen9-sponsors-contest-to-recognize-innovation-in-synthetic-biology.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254297","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254297"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254297"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254297\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}